Little is known about the interactions between ovarian hormones and responses to psychoactive drugs in humans. Preclinical studies suggest that ovarian hormones such as estrogen and progesterone have direct and indirect central nervous system actions and that these hormones can influence behavioral responses to psychoactive drugs. In the present study, we assessed the subjective and physiological effects of d-amphetamine (AMPH; 10 mg p.o.) after pretreatment with estradiol. Two groups of healthy, regularly cycling women participated in two sessions scheduled during the early follicular phases of two menstrual cycles. One group received estradiol patches (Estraderm TTS; 0.8 mg) which elevated plasma estradiol levels to approximately 750 pg/ml on both sessions; the other group received placebo patches on both sessions. Both groups received AMPH (10.0 mg) and placebo in a randomized and counterbalanced order on the two sessions. Dependent measures included self-report questionnaires, physiological measures, and plasma hormone levels. Most of the subjective and physiological effects of AMPH were not affected by acute estradiol treatment. Nevertheless, estradiol pretreatment increased the magnitude of the effects of AMPH on subjective ratings of ‘pleasant stimulation’ and decreased ratings of ‘want more’. Also, estradiol produced some subjective effects when administered alone: It increased subjective ratings of ‘feel drug’, ‘energy and intellectual efficiency’, and ‘pleasant stimulation’. These results provide limited evidence that the stimulating effects of AMPH are increased by acute estradiol pretreatment.

Keywords:
Gonadal steroids, Menstrual cycle, Amphetamines, Clinical neuroendocrinology, Behaviour
1.
Justice A, de Wit H: Acute effects of d-amphetamine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology (Berl) 1999;145:67–75.
2.
Michanek A, Meyerson BJ: Influence of estrogen and progesterone on behavioral effects of apomorphine and amphetamine. Pharmacol Biochem Behav 1982;16:875–879.
3.
Becker JB, Cha JH: Estrous cycle-dependent variation in amphetamine-induced behaviors and striatal dopamine release assessed with microdialysis. Behav Brain Res 1989;35:117–125.
4.
Becker JB, Robinson TE, Lorenz KA: Sex differences and estrous cycle variations in amphetamine-elicited rotational behavior. Eur J Pharmacol 1982;80:65–72.
5.
Becker JB, Ramirez VD: Experimental studies on the development of sex differences in the release of dopamine from striatal tissue fragments in vitro. Neuroendocrinology 1981;32:168–173.
6.
Pasqualini C, Olivier V, Guibert B, Frain O, Leviel V: Acute stimulatory effect of estradiol on striatal dopamine synthesis. J Neurochem 1995;65:1651–1657.
7.
Pasqualini C, Olivier V, Guibert B, Frain O, Leviel V: Rapid stimulation of striatal dopamine synthesis by estradiol. Cell Mol Neurobiol 1996;16:411–415.
8.
Becker JB, Beer ME: The influence of estrogen on nigrostriatal dopamine activity: Behavioral and neurochemical evidence for both pre- and postsynaptic components. Behav Brain Res 1986;19:27–33.
9.
Di Paolo T, Rouillard C, Bedard P: 17β-Estradiol at a physiological dose acutely increases dopamine turnover in rat brain. Eur J Pharmacol 1985;117:197–203.
10.
Hruska RE, Silbergeld EK: Increased dopamine receptor sensitivity after estrogen treatment using the rat rotation model. Science 1980;208:1466–1468.
11.
Rance N, Wise PM, Selmanoff MK, Barraclough CA: Catecholamine turnover rates in discrete hypothalamic areas and associated changes in median eminence luteinizing hormone-releasing hormone and serum gonadotropins on proestrus and diestrous day 1. Endocrinology 1981;108:1795–1802.
12.
Luine VN, Khylchevskaya RI, McEwen BS: Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res 1975;86:293–306.
13.
Attali G, Weizman A, Gil-Ad I, Rehavi M: Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters. Brain Res 1997;756:153–159.
14.
Disshon KA, Boja JW, Dluzen DE: Inhibition of striatal dopamine transporter activity by 17β-estradiol. Eur J Pharmacol 1998;345:207–211.
15.
Leibenluft E, Fiero PL, Rubinow DR: Effects of the menstrual cycle on dependent variables in mood disorder research [published erratum in Arch Gen Psychiatry 1995;52:144] [see Comments]. Arch Gen Psychiatry 1994;51:761–781.
16.
Griffin JE, Ojeda SR: Textbook of Endocrine Physiology, ed 3. New York, Oxford University Press, 1996, p 374.
17.
Brauer LH, de Wit H: High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacol Biochem Behav 1997;56:265–272.
18.
Derogatis L: SCL-90 Manual-II. Clinical Psychometric Research. Towson, Md., 1983.
19.
APA: Diagnostic and Statistical Manual of Psychiatry, ed 4. Washington, American Psychiatric Press, 1994.
20.
McNair D, Lorr M, Droppleman L: Profile of Mood States. San Diego, Educational and Industrial Testing Service, 1971.
21.
Martin WR, Sloan JW, Sapira JD, Jasinski DR: Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971;12:245–258.
22.
Fischman MW, Foltin RW: Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 1991;86:1563–1570.
23.
Sofuoglu M, Dudish-Poulsen S, Nelsen D, Pentel RR, Hatsukami DK: Subjective effects of cocaine are altered by gender and menstrual cycle phase in humans. NIDA Res Monogr 1998;179:150.
24.
Peris J, Decambre N, Coleman-Hardee ML, Simpkins JW: Estradiol enhances behavioral sensitization to cocaine and amphetamine-stimulated striatal [3H]dopamine release. Brain Res 1991;566:255–264.
25.
Dluzen DE, Ramirez VD: Bimodal effect of progesterone on in vitro dopamine function of the rat corpus striatum. Neuroendocrinology 1984;39:149–155.
26.
Dluzen DE, Ramirez VD: Intermittent infusion of progesterone potentiates whereas continuous infusion reduces amphetamine-stimulated dopamine release from ovariectomized estrogen-primed rat striatal fragments superfused in vitro. Brain Res 1987;406:1–9.
27.
Bazzett TJ, Becker JB: Sex differences in the rapid and acute effects of estrogen on striatal D2 dopamine receptor binding. Brain Res 1994;637:163–172.
28.
Sell SL, Thomas ML, Cunningham KA: The influence of the estrous cycle on locomotor hyperactivity evoked by cocaine. NIDA Res Monogr 1998;179:148.
29.
Levesque D, Di Paolo T: Chronic estradiol treatment increases ovariectomized rat striatal D-1 dopamine receptors. Life Sci 1989;45:1813–1820.
30.
Levesque D, Di Paolo T: Modulation by estradiol and progesterone of the GTP effect on striatal D-2 dopamine receptors. Biochem Pharmacol 1993;45:723–733.
31.
Lukas SE, Sholar M, Lundahl LH, Lamas X, Kouri E, Wines JD, Kragie L, Mendelson JH: Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. Psychopharmacology (Berl) 1996;125:346–354.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.